Lifeward Ltd.
LFWDNasdaq
$7.91
↑ +0.9%Jul 17 close · end-of-day
Price
1Y↓ -10.9%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$12.7M
Enterprise Value
$1.3M
P/E
—
P/S
0.6
P/B
2.0
EV/EBITDA
—
PEG
—
FCF Yield
-117.9%
Dividend Yield
—
Revenue (TTM)
$20.9M
Net Income (TTM)
-$25.9M
Free Cash Flow (TTM)
-$15.0M
Gross Margin
36.5%
Operating Margin
-120.2%
Net Margin
-123.7%
ROE
-411.3%
ROIC
—
Debt / Equity
—
Net Cash
$11.4M
Return 1Y
-11.3%
Company profile
ReWalk Robotics Ltd. designs, develops, and commercializes robotic exoskeletons for individuals with mobility impairments or other medical conditions. The company offers ReWalk Personal and ReWalk Rehabilitation for spinal cord injuries and everyday use by paraplegic individuals at home and in communities. ReStore is a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke in the clinical rehabilitation environment.
- CEO
- Lawrence J. Jasinski
- Sector
- Manufacturing
- Industry
- Medical Equipment
- Employees
- 60
- Headquarters
- Massachusetts
- Website
- rewalk.com
Management & directors
- Rose Keith DaleChief Medical Officer
- Lynch JeannineVP of Market Access & Strategy
Roles derived from SEC Form 4 filings.
Earnings
LFWD Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$3.9M↓ -22.1%
Diluted EPS-$6.70↑ +21.2%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $4.4M | $6.0M | $5.5M | $13.9M | $25.7M | $22.0M |
| Gross profit | $2.2M | $2.9M | $1.9M | $4.5M | $8.2M | $8.4M |
| Operating income | -$12.0M | -$12.7M | -$19.1M | -$23.6M | -$29.3M | -$19.7M |
| Net income | -$13.0M | -$12.7M | -$19.6M | -$22.1M | -$28.9M | -$19.9M |
| Diluted EPS | -$0.82 | -$0.27 | -$2.20 | -$31.13 | -$39.96 | -$17.16 |
| Operating cash flow | -$12.6M | -$11.5M | -$17.9M | -$20.7M | -$21.7M | -$16.8M |
| Free cash flow | -$12.7M | -$11.5M | -$17.9M | -$20.7M | -$21.7M | -$16.8M |
| Gross margin | 49.8% | 48.7% | 34.6% | 32.1% | 32.0% | 38.2% |
| Operating margin | -273.3% | -212.1% | -346.6% | -170.4% | -114.4% | -89.3% |
| Net margin | -295.4% | -213.5% | -355.1% | -159.8% | -112.8% | -90.4% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $6.7M | $6.1M | $7.5M | $5.0M | $5.7M | $6.2M | $5.1M | $3.9M |
| Gross profit | $2.8M | $2.2M | $1.8M | $2.1M | $2.5M | $2.7M | $1.1M | $1.3M |
| Operating income | -$4.4M | -$3.2M | -$15.2M | -$4.9M | -$6.6M | -$3.1M | -$5.1M | -$10.3M |
| Net income | -$4.3M | -$3.1M | -$15.3M | -$4.8M | -$6.6M | -$3.2M | -$5.3M | -$10.8M |
| Diluted EPS | -$0.50 | -$0.35 | -$38.38 | -$5.53 | -$0.58 | -$0.20 | -$10.85 | -$6.70 |
| Operating cash flow | -$5.6M | -$4.5M | -$4.0M | -$5.5M | -$3.9M | -$3.8M | -$3.6M | -$3.7M |
| Free cash flow | -$5.6M | -$4.5M | -$4.0M | -$5.5M | -$3.9M | -$3.8M | -$3.6M | -$3.7M |
| Gross margin | 41.1% | 36.2% | 24.4% | 42.2% | 43.9% | 43.7% | 21.4% | 34.2% |
| Operating margin | -66.2% | -51.8% | -201.8% | -96.4% | -114.7% | -50.7% | -100.7% | -263.5% |
| Net margin | -64.2% | -50.3% | -202.5% | -96.0% | -114.6% | -51.2% | -105.3% | -275.1% |
Company news
May 15, 2026
- 65d agoLifeward Ltd (LFWD) Q1 2026 Earnings Call Highlights: Navigating Challenges and Seizing Growth ...finance.yahoo.com
- 66d agoLifeward (LFWD) Q1 2026 Earnings Transcriptfool.com
- 66d agoLifeward Ltd. Q1 2026 Earnings Call Summaryapp.moby.co
- 66d agoLifeward (LFWD) Reports Q1 Loss, Lags Revenue Estimatesfinance.yahoo.com
- 66d agoLifeward Reports First Quarter 2026 Financial Resultsfinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-05-01 | Rose Keith Dale· Chief Medical Officer | Award | 15,000 | $0.00 | $0.00 | filing |
| 2026-03-25 | Sigsbee William Mark | Award | 11,485 | $0.00 | $0.00 | filing |
| 2026-03-25 | Rozenbaum Moshe H | Award | 11,485 | $0.00 | $0.00 | filing |
| 2026-03-25 | Reznick Yehuda | Award | 7,657 | $0.00 | $0.00 | filing |
| 2026-03-25 | KIDRON NADAV | Award | 7,657 | $0.00 | $0.00 | filing |
| 2026-03-25 | Kidron Miriam | Award | 7,657 | $0.00 | $0.00 | filing |
| 2025-12-11 | Lynch Jeannine· VP of Market Access & Strategy | Award | 50,000 | $0.00 | $0.00 | filing |
| 2025-09-02 | Lynch Jeannine· VP of Market Access & Strategy | Sale | 1,591 | $0.64 | $1,018.24 | filing |
| 2025-08-01 | Richner Randel | Award | 35,920 | $0.00 | $0.00 | filing |
| 2025-08-01 | Levy Hadar | Award | 35,920 | $0.00 | $0.00 | filing |
| 2025-08-01 | Turk Joseph E Jr | Award | 71,839 | $0.00 | $0.00 | filing |
| 2025-08-01 | PODUSKA JOHN WILLIAM SR | Award | 35,920 | $0.00 | $0.00 | filing |
| 2025-08-01 | Marshall Robert J. Jr. | Award | 35,920 | $0.00 | $0.00 | filing |
| 2025-08-01 | Swinford Michael | Award | 35,920 | $0.00 | $0.00 | filing |
Latest 14 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.